EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Open Access · CC BY 4.0

Targeting IGF2 to reprogram the tumor microenvironment for enhanced viro-immunotherapy

Min Hye Noh, Jin Muk Kang, Alexandra A Miller, Grace Nguyen, Minxin Huang, Ji Seon Shim, Alberto J Bueso-Perez, Sara A Murphy, Kimberly A Rivera-Caraballo, Yoshihiro Otani, Eunju Kim, Seung-Hee Yoo und 8 weitere

Neuro-Oncology · 05.09.2024 · 26 (9) · 1602-1616

DOI: 10.1093/neuonc/noae105 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Neuro-Oncology, online erschienen am 10.06.2024. Verfasst von Min Hye Noh und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, Texas, USA. Hauptthemen laut MEDLINE: Brain Neoplasms, Immunotherapy, Insulin-Like Growth Factor II, Oncolytic Virotherapy. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NINDS NIH HHS, NCI NIH HHS, American Cancer Society.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The FDA approval of oncolytic herpes simplex-1 virus (oHSV) therapy underscores its therapeutic promise and safety as a cancer immunotherapy. Despite this promise, the current efficacy of oHSV is significantly limited to a small subset of patients largely due to the resistance in tumor and tumor microenvironment (TME).

Methods

RNA sequencing (RNA-Seq) was used to identify molecular targets of oHSV resistance. Intracranial human and murine glioma or breast cancer brain metastasis (BCBM) tumor-bearing mouse models were employed to elucidate the mechanism underlying oHSV therapy-induced resistance.

Results

Transcriptome analysis identified IGF2 as one of the top-secreted proteins following oHSV treatment. Moreover, IGF2 expression was significantly upregulated in 10 out of 14 recurrent GBM patients after treatment with oHSV, rQNestin34.5v.2 (71.4%; P = .0020) (ClinicalTrials.gov, NCT03152318). Depletion of IGF2 substantially enhanced oHSV-mediated tumor cell killing in vitro and improved survival of mice bearing BCBM tumors in vivo. To mitigate the oHSV-induced IGF2 in the TME, we constructed a novel oHSV, oHSV-D11mt, secreting a modified IGF2R domain 11 (IGF2RD11mt) that acts as IGF2 decoy receptor. Selective blocking of IGF2 by IGF2RD11mt significantly increased cytotoxicity, reduced oHSV-induced neutrophils/PMN-MDSCs infiltration, and reduced secretion of immune suppressive/proangiogenic cytokines, while increased CD8 + cytotoxic T lymphocytes (CTLs) infiltration, leading to enhanced survival in GBM or BCBM tumor-bearing mice.

Conclusions

This is the first study reporting that oHSV-induced secreted IGF2 exerts a critical role in resistance to oHSV therapy, which can be overcome by oHSV-D11mt as a promising therapeutic advance for enhanced viro-immunotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Brain NeoplasmsImmunotherapyInsulin-Like Growth Factor IIOncolytic VirotherapyTumor MicroenvironmentAnimalsFemaleHumansMiceBreast NeoplasmsGlioblastomaGliomaHerpesvirus 1, HumanOncolytic VirusesTumor Cells, CulturedXenograft Model Antitumor Assays

Stichwörter der Autor:innen

Oncolytic herpes simplex virus-1 (oHSV)glioblastoma (GBM)insulin-like growth factor 2 (IGF2)insulin-like growth factor-1 receptor (IGF1R)tumor microenvironment (TME)

Substanzen

IGF2 protein, humanInsulin-Like Growth Factor II

Autor:innen und Institutionen

  • Department of Neurosurgery, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, Texas, USA.
  • Department of Pediatric Hematology & Oncology, University Hospitals Cleveland Medical Center, Cleveland, Ohio, USA.
  • The University of Texas MD Anderson Cancer Center UTHealth Houston Graduate School of Biomedical Science, Houston, Texas, USA.
  • Georgia Cancer Center and Department of Pathology, Medical College of Georgia, Augusta University, Augusta, Georgia, USA.
  • Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan.
  • Department of Food and Nutriton, Kongju National University, Yesan, Chungnam, South Korea.

ORCID-Profile: Zhongming Zhao, Ji Young Yoo

Förderung

  • NINDS NIH HHS
  • NCI NIH HHS
  • American Cancer Society
  • NIH HHS
  • National Institutes of Health

Zitieren

APA

Noh, M. H., Kang, J. M., Miller, A. A., Nguyen, G., Huang, M., Shim, J. S., Bueso-Perez, A. J., Murphy, S. A., Rivera-Caraballo, K. A., Otani, Y., Kim, E., Yoo, S. H., Yan, Y., Banasavadi-Siddegowda, Y., Nakashima, H., Chiocca, E. A., Kaur, B., Zhao, Z., Lee, T. J., & Yoo, J. Y. (2024). Targeting IGF2 to reprogram the tumor microenvironment for enhanced viro-immunotherapy. Neuro-Oncology, 26(9), 1602-1616. https://doi.org/10.1093/neuonc/noae105

Vancouver

Noh MH, Kang JM, Miller AA, Nguyen G, Huang M, Shim JS, et al. Targeting IGF2 to reprogram the tumor microenvironment for enhanced viro-immunotherapy. Neuro-Oncology. 2024;26(9):1602-1616. doi:10.1093/neuonc/noae105

BibTeX
@article{Noh2024,
  author = {Noh, Min Hye and Kang, Jin Muk and Miller, Alexandra A and Nguyen, Grace and Huang, Minxin and Shim, Ji Seon and Bueso-Perez, Alberto J and Murphy, Sara A and Rivera-Caraballo, Kimberly A and Otani, Yoshihiro and Kim, Eunju and Yoo, Seung-Hee and Yan, Yuanqing and Banasavadi-Siddegowda, Yeshavanth and Nakashima, Hiroshi and Chiocca, E Antonio and Kaur, Balveen and Zhao, Zhongming and Lee, Tae Jin and Yoo, Ji Young},
  title = {Targeting IGF2 to reprogram the tumor microenvironment for enhanced viro-immunotherapy},
  journal = {Neuro-Oncology},
  year = {2024},
  volume = {26},
  number = {9},
  pages = {1602--1616},
  doi = {10.1093/neuonc/noae105}
}
Kostenlos starten →